Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Boehringer Ingelheim
Chubb
UBS
Medtronic
Covington
US Army
Colorcon
McKesson
AstraZeneca

Generated: August 21, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
Abstract: The present invention describes processes for the preparation of a lipid blend and a uniform filterable phospholipid suspension containing the lipid blend, such suspension being useful as an ultrasound contrast agent.
Inventor(s): Hui; Poh K. (Wellesley Hills, MA), Bishop; John E. (Groton, MA), Madrigal, Jr.; Eleodoro S. (Westford, MA)
Assignee: Lantheus Medical Imaging, Inc. (North Billerica, MA)
Filing Date:Jul 25, 2013
Application Number:13/950,348
Claims:1. A process for preparing a lipid suspension for use with a perfluorocarbon gas as an ultrasound contrast agent, the method comprising: (a) contacting phospholipids with a first non-aqueous solvent which causes the phospholipids to dissolve and form a lipid solution, wherein the contacting comprises the sequential addition of individual phospholipids to the first non-aqueous solvent wherein the phospholipids are 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid, mono sodium salt (DPPA) and N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, mono sodium salt (MPEG5000-DPPE), or combining said phospholipids with each other prior to their addition to the first non-aqueous solvent; (b) contacting the non-aqueous lipid solution of (a) with a second non-aqueous solvent which causes the phospholipids to precipitate out as a solid lipid blend; (c) collecting the solid lipid blend; (d) contacting the solid lipid blend with a third non-aqueous solvent which causes the lipid blend to dissolve to form a lipid blend solution; (e) contacting the lipid blend solution with an aqueous solution to yield the lipid suspension; and (f) filtering the lipid suspension through one or two sterilizing filters to form a filtered lipid suspension.

2. The process of claim 1, wherein the one or two sterilizing filters are 0.2 micron filters.

3. The process of claim 1, further comprising dispensing the filtered lipid suspension into a vial.

4. The process of claim 3, further comprising exchanging the headspace gas of the vial with the perfluorocarbon gas.

5. The process of claim 4, wherein the perfluorocarbon gas is perfluoropropane.

6. The process of claim 4, further comprising sterilizing the vial.

7. The process of claim 6, wherein the vial is sterilized at about 126-130.degree. C. for 1 to 10 minutes.

8. The process of claim 1, wherein (i) the first non-aqueous solvent is a mixture of methanol and toluene; (ii) the second non-aqueous solvent is methyl t-butyl ether; (iii) the third non-aqueous solvent is propylene glycol; (iv) the aqueous solution comprises sodium chloride, glycerin, and propylene glycol.

9. The process of claim 8, wherein (i) the third non-aqueous solvent is heated to a temperature of about 50-60.degree. C. prior to contacting with the solid lipid blend; (ii) the aqueous solution is heated to a temperature of about 45-60.degree. C. prior to contacting with the lipid blend solution.

10. The process of claim 3, wherein (i) the first non-aqueous solvent is a mixture of methanol and toluene; (ii) the second non-aqueous solvent is methyl t-butyl ether; (iii) the third non-aqueous solvent is propylene glycol; (iv) the aqueous solution comprises sodium chloride, glycerin, and propylene glycol.

11. The process of claim 10, wherein (i) the third non-aqueous solvent is heated to a temperature of about 50-60.degree. C. prior to contacting with the solid lipid blend; (ii) the aqueous solution is heated to a temperature of about 45-60.degree. C. prior to contacting with the lipid blend solution.

12. The process of claim 4, wherein (i) the first non-aqueous solvent is a mixture of methanol and toluene; (ii) the second non-aqueous solvent is methyl t-butyl ether; (iii) the third non-aqueous solvent is propylene glycol; (iv) the aqueous solution comprises sodium chloride, glycerin, and propylene glycol.

13. The process of claim 12, wherein (i) the third non-aqueous solvent is heated to a temperature of about 50-60.degree. C. prior to contacting with the solid lipid blend; (ii) the aqueous solution is heated to a temperature of about 45-60.degree. C. prior to contacting with the lipid blend solution.

14. The process of claim 5, wherein (i) the first non-aqueous solvent is a mixture of methanol and toluene; (ii) the second non-aqueous solvent is methyl t-butyl ether; (iii) the third non-aqueous solvent is propylene glycol; (iv) the aqueous solution comprises sodium chloride, glycerin, and propylene glycol.

15. The process of claim 14, wherein (i) the third non-aqueous solvent is heated to a temperature of about 50-60.degree. C. prior to contacting with the solid lipid blend; (ii) the aqueous solution is heated to a temperature of about 45-60.degree. C. prior to contacting with the lipid blend solution.

16. The process of claim 6, wherein (i) the first non-aqueous solvent is a mixture of methanol and toluene; (ii) the second non-aqueous solvent is methyl t-butyl ether; (iii) the third non-aqueous solvent is propylene glycol; (iv) the aqueous solution comprises sodium chloride, glycerin, and propylene glycol.

17. The process of claim 16, wherein (i) the third non-aqueous solvent is heated to a temperature of about 50-60.degree. C. prior to contacting with the solid lipid blend; (ii) the aqueous solution is heated to a temperature of about 45-60.degree. C. prior to contacting with the lipid blend solution.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Fish and Richardson
Fuji
Boehringer Ingelheim
Baxter
Novartis
Federal Trade Commission
Citi
Medtronic
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot